New frontier: Gene silencing technology

Benitec's first 'DNA directed ribonucleic acid (RNA) interference' (ddRNAi) therapeutic, TT-034, is being tested in an ongoing Phase Ib/IIa clinical trial for the treatment of hepatitis C. This clinical trial represents a significant milestone both for Benitec as a company and potentially for the field of gene therapy as a whole.